The CALLA Phase III trial for AstraZeneca’s Imfinzi given concurrently with chemoradiotherapy (CRT) did not achieve statistical significance for the primary endpoint of improving progression-free survival (PFS) versus CRT alone in the treatment of patients with locally advanced cervical cancer.
“CALLA tested a novel immunotherapy approach in locally advanced cervical cancer, a devastating and complex disease where many patients progress following available treatments. While the results were not what we hoped for, insights from the trial will advance our understanding and application of immunotherapy across our broad clinical development programme, exploring the benefits of Imfinzi in many tumor types,” says Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca.
The safety and tolerability in this trial were consistent between the two arms and no new unexpected safety findings were observed.
Photo of Susan Galbraith: AstraZeneca